dildo and breast play - hera and herceptin and breast


hera and herceptin and breast - dildo and breast play

The Herceptin Adjuvant (HERA) (Breast International Group [BIG] ) Trial is an international, intergroup, open-label, phase 3 randomized trial involving women with HER2-positive Cited by: HERA (BIG ) is an international, multicentre, open-label, phase 3 randomised trial of women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries between Dec 7, , and June 20, Cited by:

The FDA later expanded the indication of Herceptin to be used as monotherapy for the adjuvant treatment of HER2 - positive breast cancer based on follow-up results from HERA, in which a group of patients on Herceptin monotherapy following combination therapy had a 46% reduction in recurrences compared to those who were not on Herceptin. Sep 01,  · Motivated by the proven benefits of trastuzumab therapy in metastatic breast cancer, four major international studies of adjuvant trastuzumab with a planned enrollment of >13, women with HERpositive EBC were initiated in – the Herceptin ® Adjuvant (HERA) trial, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B Cited by:

Roche (SIX: RO, ROG; OTCQX: RHHBY) and the Breast International Group (BIG) today announced final results from the Phase III HERA trial, which confirmed that one year of Herceptin(trastuzumab) treatment remains the standard of care for people with early-stage HER2-positive breast . Feb 24,  · The Herceptin Adjuvant (HERA) international study included more than 5, women with HER2-positive, early-stage breast cancers enrolled between December and June